{"id":15290,"date":"2023-01-17T00:29:00","date_gmt":"2023-01-17T00:29:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3988100_AE88100_0"},"modified":"2023-01-17T00:29:00","modified_gmt":"2023-01-17T00:29:00","slug":"ascletis-announces-entering-into-a-supply-agreement-of-ritonavir-tablets-with-simcere","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=15290","title":{"rendered":"Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere"},"content":{"rendered":"<div><img decoding=\"async\" src=\"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png\" class=\"ff-og-image-inserted\"><\/div>\n<div id=\"dvContent\" readability=\"68.294117647059\">\n<p><span class=\"xn-location\">HANGZHOU<\/span> and SHAOXING, <span class=\"xn-location\">China<\/span>, <span class=\"xn-chron\">Jan. 17, 2023<\/span> \/PRNewswire\/ &#8212; Ascletis Pharma Inc. (HKEX: 1672, &#8220;Ascletis&#8221;) today announces that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, &#8220;Simcere&#8221;).<\/p>\n<p>Ritonavir tablet is a pharmacokinetic booster of multiple oral antiviral protease inhibitors. Ascletis currently owns the only authorized ritonavir oral tablet in <span class=\"xn-location\">China<\/span>, which has passed bioequivalence study.<\/p>\n<p><b>About Ascletis<\/b><\/p>\n<p>Ascletis is an innovative R&amp;D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and a proven track record, Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. Through excellent execution, Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. To date, Ascletis has three marketed products, i.e. ritonavir tablets, GANOVO<sup>\u00ae<\/sup> and ASCLEVIR<sup>\u00ae<\/sup>, and 22 drug candidates in its R&amp;D pipeline. The most advanced drug candidates include ASC22 (CHB functional cure), ASC10 and ASC11(oral small molecules for COVID-19 treatment), ASC40 (recurrent glioblastoma), ASC42 (PBC, primary biliary cholangitis), and ASC40 (acne).<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.ascletis.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.ascletis.com<\/a>.<\/p>\n<\/p><\/div>\n<p>Source: Ascletis Pharma Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HANGZHOU and SHAOXING, China, Jan. 17, 2023 \/PRNewswire\/ &#8212; Ascletis Pharma Inc. (HKEX: 1672, &#8220;Ascletis&#8221;) today announces that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, &#8220;Simcere&#8221;). Ritonavir tablet is a [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-15290","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=15290\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere - My Blog\" \/>\n<meta property=\"og:description\" content=\"HANGZHOU and SHAOXING, China, Jan. 17, 2023 \/PRNewswire\/ &#8212; Ascletis Pharma Inc. (HKEX: 1672, &#8220;Ascletis&#8221;) today announces that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, &#8220;Simcere&#8221;). Ritonavir tablet is a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=15290\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-17T00:29:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=15290#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=15290\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere\",\"datePublished\":\"2023-01-17T00:29:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=15290\"},\"wordCount\":235,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=15290#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/en.prnasia.com\\\/prnasia.com-PC\\\/images\\\/logo-en-blue-in.png\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=15290\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=15290\",\"name\":\"Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=15290#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=15290#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/en.prnasia.com\\\/prnasia.com-PC\\\/images\\\/logo-en-blue-in.png\",\"datePublished\":\"2023-01-17T00:29:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=15290#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=15290\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=15290#primaryimage\",\"url\":\"https:\\\/\\\/en.prnasia.com\\\/prnasia.com-PC\\\/images\\\/logo-en-blue-in.png\",\"contentUrl\":\"https:\\\/\\\/en.prnasia.com\\\/prnasia.com-PC\\\/images\\\/logo-en-blue-in.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=15290#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=15290","og_locale":"en_US","og_type":"article","og_title":"Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere - My Blog","og_description":"HANGZHOU and SHAOXING, China, Jan. 17, 2023 \/PRNewswire\/ &#8212; Ascletis Pharma Inc. (HKEX: 1672, &#8220;Ascletis&#8221;) today announces that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, &#8220;Simcere&#8221;). Ritonavir tablet is a [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=15290","og_site_name":"My Blog","article_published_time":"2023-01-17T00:29:00+00:00","og_image":[{"url":"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=15290#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=15290"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere","datePublished":"2023-01-17T00:29:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=15290"},"wordCount":235,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=15290#primaryimage"},"thumbnailUrl":"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=15290","url":"https:\/\/transmediavictoria.net.au\/?p=15290","name":"Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=15290#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=15290#primaryimage"},"thumbnailUrl":"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png","datePublished":"2023-01-17T00:29:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=15290#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=15290"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=15290#primaryimage","url":"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png","contentUrl":"https:\/\/en.prnasia.com\/prnasia.com-PC\/images\/logo-en-blue-in.png"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=15290#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/15290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15290"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/15290\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}